{"transactions":[{"id":743627,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T00:00:56.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":13587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":13587,"derivative":{"exercise_price":11,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13587},"source":{"system":"sec-edgar","filing":"0001193125-26-266276","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526266276/ownership.xml","form_type":"4"}},{"id":1278866,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:43:00.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":3511,"price":13.7611,"value":48315.2221,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (\"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":443885,"source":{"system":"sec-edgar","filing":"0000950170-25-016385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025016385/ownership.xml","form_type":"4"}},{"id":1278865,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:43:00.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":1890,"price":13.7611,"value":26008.479,"ownership":{"direct":false,"nature":"By Canaan XI L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3700705,"source":{"system":"sec-edgar","filing":"0000950170-25-016385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025016385/ownership.xml","form_type":"4"}},{"id":1294582,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-27T22:09:15.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":4825,"price":16.2624,"value":78466.08,"ownership":{"direct":false,"nature":"By Canaan XI L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3702595,"source":{"system":"sec-edgar","filing":"0000950170-25-009278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025009278/ownership.xml","form_type":"4"}},{"id":1298859,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-21","kind":"sale","planned":false,"acquired":false,"shares":3993,"price":16.3626,"value":65335.8618,"ownership":{"direct":false,"nature":"By Canaan XI L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer,\nor the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3707420,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298858,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":461,"price":16.4001,"value":7560.4461,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":447396,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298857,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":12808,"price":16.4001,"value":210052.4808,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3711413,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298856,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":835,"price":16.287,"value":13599.645,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":447857,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298855,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":6944,"price":16.287,"value":113096.928,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3724221,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1351160,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:47:24.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":566,"price":16.8386,"value":9530.6476,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":448692,"source":{"system":"sec-edgar","filing":"0000950170-24-131084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024131084/ownership.xml","form_type":"4"}},{"id":1351159,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:47:24.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":4706,"price":16.8386,"value":79242.4516,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3731165,"source":{"system":"sec-edgar","filing":"0000950170-24-131084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024131084/ownership.xml","form_type":"4"}},{"id":1371568,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-07","kind":"sale","planned":false,"acquired":false,"shares":2371,"price":17.3181,"value":41061.2151,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":449258,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1371567,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-07","kind":"sale","planned":false,"acquired":false,"shares":19720,"price":17.3181,"value":341512.932,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3735871,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1371566,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-06","kind":"sale","planned":false,"acquired":false,"shares":5635,"price":17.1755,"value":96783.9425,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":451629,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1371565,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-06","kind":"sale","planned":false,"acquired":false,"shares":46856,"price":17.1755,"value":804775.228,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3755591,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1374351,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":1126,"price":16.7683,"value":18881.1058,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":457264,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1374350,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":9367,"price":16.7683,"value":157068.6661,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3802447,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1374349,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-04","kind":"sale","planned":false,"acquired":false,"shares":116,"price":17.006,"value":1972.696,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":458390,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1374348,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-04","kind":"sale","planned":false,"acquired":false,"shares":960,"price":17.006,"value":16325.76,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3811814,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1378291,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":73,"price":17.1594,"value":1252.6362,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":458506,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378290,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":2878,"price":16.5444,"value":47614.7832,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":458579,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378289,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Commmon Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":604,"price":17.1594,"value":10364.2776,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3812774,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378288,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":23938,"price":16.5444,"value":396039.8472,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3813378,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378287,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-31","kind":"sale","planned":false,"acquired":false,"shares":10750,"price":16.4596,"value":176940.7,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":461457,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378286,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-31","kind":"sale","planned":false,"acquired":false,"shares":89390,"price":16.4596,"value":1471323.644,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3837316,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378285,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-30","kind":"sale","planned":false,"acquired":false,"shares":1189,"price":16.169,"value":19224.941,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":472207,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378284,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-30","kind":"sale","planned":false,"acquired":false,"shares":9889,"price":16.169,"value":159895.241,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3926706,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1496805,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:30:04.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":18600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":18600,"derivative":{"exercise_price":15.94,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0000950170-24-067351","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024067351/ownership.xml","form_type":"4"}},{"id":1870266,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T20:31:14.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":14500,"derivative":{"exercise_price":14.47,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001209191-23-033774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000120919123033774/doc4.xml","form_type":"4"}},{"id":2231611,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-15T20:46:52.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 13, 2022, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders,  subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":14500,"derivative":{"exercise_price":5.38,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001209191-22-036979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000120919122036979/doc4.xml","form_type":"4"}},{"id":2564183,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-20T22:36:16.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182258,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473396},"source":{"system":"sec-edgar","filing":"0000899243-21-036637","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036637/doc4a.xml","form_type":"4/A","original_submission_date":"2021-09-17"}},{"id":2564182,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-20T22:36:16.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182257,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473394},"source":{"system":"sec-edgar","filing":"0000899243-21-036637","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036637/doc4a.xml","form_type":"4/A","original_submission_date":"2021-09-17"}},{"id":2564181,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-09-20T22:36:16.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1333334,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3463201},"source":{"system":"sec-edgar","filing":"0000899243-21-036637","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036637/doc4a.xml","form_type":"4/A","original_submission_date":"2021-09-17"}},{"id":2564180,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:36:16.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":473396,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":473396,"source":{"system":"sec-edgar","filing":"0000899243-21-036637","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036637/doc4a.xml","form_type":"4/A","original_submission_date":"2021-09-17"}},{"id":2564179,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T22:36:16.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":3936595,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3936595,"source":{"system":"sec-edgar","filing":"0000899243-21-036637","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036637/doc4a.xml","form_type":"4/A","original_submission_date":"2021-09-17"}},{"id":2566262,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-17T20:39:33.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182258,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473396},"source":{"system":"sec-edgar","filing":"0000899243-21-036420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036420/doc4.xml","form_type":"4"}},{"id":2566261,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-17T20:39:33.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182257,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473394},"source":{"system":"sec-edgar","filing":"0000899243-21-036420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036420/doc4.xml","form_type":"4"}},{"id":2566260,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-09-17T20:39:33.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1333334,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3463201},"source":{"system":"sec-edgar","filing":"0000899243-21-036420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036420/doc4.xml","form_type":"4"}},{"id":2566259,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:39:33.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":473396,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":473396,"source":{"system":"sec-edgar","filing":"0000899243-21-036420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036420/doc4.xml","form_type":"4"}},{"id":2566258,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:39:33.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":3936595,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3963595,"source":{"system":"sec-edgar","filing":"0000899243-21-036420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036420/doc4.xml","form_type":"4"}},{"id":4136241,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:25:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.26,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-17-028423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028423/doc4.xml","form_type":"4"}},{"id":4136240,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:25:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.76,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-17-028423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028423/doc4.xml","form_type":"4"}},{"id":4136239,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:25:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.84,"expiration_date":"2024-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-17-028423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028423/doc4.xml","form_type":"4"}},{"id":4136238,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:25:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.85,"expiration_date":"2023-12-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-028423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028423/doc4.xml","form_type":"4"}},{"id":4136237,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-11T15:25:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":12500,"price":1.52,"value":19000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the \"Issuer\"),  MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the \"Shares\"), of the Issuer outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the \"CVR Agreement\"), entered  into on December 7, 2017  to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-028423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028423/doc4.xml","form_type":"4"}},{"id":4274425,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T16:40:46.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units shall vest in full on the earlier of the one year anniversary of the grant or the next annual meeting of shareholders; provided, in all cases, that the Reporting Person is, as of each such vesting date, then a director of the Issuer."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001274644-17-000057","document":"wf-form4_149816403160205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000127464417000057/wf-form4_149816403160205.xml","form_type":"4"}},{"id":4352002,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-14T14:32:05.000Z","date":"2017-04-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over 12 months measured from April 12, 2017 subject to Reporting Person's continuous service status as of each such date."}],"balance_after":10000,"derivative":{"exercise_price":8.5,"expiration_date":"2027-04-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-026970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1305253/000120919117026970/doc4.xml","form_type":"4"}},{"id":4602487,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-15T18:46:19.000Z","date":"2016-03-28","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant was approved by Issuer's board of directors on March 28, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the \"Plan\") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016."}],"balance_after":25000,"derivative":{"exercise_price":15.75,"expiration_date":"2026-03-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-16-141651","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1305253/000120919116141651/doc4a.xml","form_type":"4/A","original_submission_date":"2016-04-01"}}]}